Skip to main content
KALA
NASDAQ Life Sciences

KALA BIO Settles $10.6M Debt for $2M, Eliminating Significant Financial Obligation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.621
Mkt Cap
$13.621M
52W Low
$0.51
52W High
$20.6
52W Position info
22% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

KALA sits 22% above its 52-week low of $0.51 on light trading volume (0.1× avg).

Summary

KALA BIO, Inc. has successfully settled a $10.6 million loan agreement with Oxford Finance, LLC for a payment of $2 million, significantly reducing its liabilities.


Key Events · Financing and Capital Events · KALA

  • Debt Settlement Completed

    KALA BIO paid Oxford Finance, LLC $2 million on December 26, 2025, as per a previously disclosed Loan Settlement Agreement.

  • Significant Liability Reduction

    This payment satisfied all obligations under the Settlement Agreement and the original Loan Agreement, settling an aggregate liability of approximately $10.6 million.

  • Improved Financial Position

    The settlement effectively reduced the company's total liabilities by $8.6 million, removing a substantial financial burden.


Analysis · KALA · Life Sciences

This 8-K filing reports a highly material financial event for KALA BIO. By settling a $10.6 million debt for a $2 million payment, the company has effectively reduced its liabilities by $8.6 million. This substantial debt reduction significantly improves its balance sheet and removes a major financial overhang. For a micro-cap company, eliminating such a large obligation can be a critical step towards financial stability and future growth, potentially attracting new investors or improving creditworthiness.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KALA was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $0.51 to $20.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KALA - Latest Insights

KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.570 info
Change: -$0.020 (-3%) info
Market Cap: $11.07M info
KALA
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.538
Real-time Price: $0.570 info
Change: +$0.032 (+6%) info
Market Cap: $11.07M info
KALA
Aug 28, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.795
Real-time Price: $0.570 info
Change: -$0.225 (-28%) info
Market Cap: $11.07M info
KALA
Aug 19, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.900
Real-time Price: $0.570 info
Change: -$0.330 (-37%) info
Market Cap: $11.07M info
KALA
Jul 22, 2026, 6:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.720
Real-time Price: $0.570 info
Change: -$0.150 (-21%) info
Market Cap: $11.07M info